MaaT Pharma has seen its microbiome therapy for patients living with treatment-induced dysbiosis hit its endpoints.

Viking Therapeutics has begun a Phase II clinical trial of VK2735 aimed at treating metabolic disorders, such as obesity.

Suven Life Sciences has announced the dosing of the first subjects in its Phase I clinical trial of SUVN-I6107 to treat cognitive disorders.

Cervical cancer begins in the cells of the cervix and is primarily caused by the human papillomavirus (HPV), a common sexually transmitted virus.

The company says the early trial of its hair-loss therapy saw patients benefit from six times more hair growth than placebo.

Ryght AI has announced a strategic collaboration with QPS Holdings for optimising clinical trial processes globally.

ISM5411 was well tolerated and demonstrated a favourable pharmokinetic profile in validating gut-restrictive properties.

RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.

J&J has reported positive topline outcomes from the MARIPOSA trial of RYBREVANT and LAZCLUZE combo for NSCLC treatment.

BIAL has completed the full dose regimen for the first subject in the Phase II ACTIVATE trial of BIA 28-6156, for Parkinson's treatment.

Denali Therapeutics has reported that its Phase II/III HEALEY ALS Platform trial of DNL343 for ALS failed to meet its primary endpoint.

Data from the largest US Lyme disease registry suggests that 90% of PLD patients are excluded from clinical trials.